Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy
Authors
Keywords
-
Journal
CLINICAL CANCER RESEARCH
Volume 29, Issue 10, Pages 1916-1928
Publisher
American Association for Cancer Research (AACR)
Online
2023-03-15
DOI
10.1158/1078-0432.ccr-22-3291
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells
- (2022) Martin K. Bakht et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
- (2022) Ning Zhao et al. CLINICAL CANCER RESEARCH
- Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC).
- (2022) Rahul Raj Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
- (2021) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors
- (2020) Tom A. Bäck et al. EJNMMI Research
- PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
- (2020) Wallace Jones et al. Cancers
- A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration
- (2020) Beihe Wang et al. CLINICAL CANCER RESEARCH
- Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET
- (2020) Sinan Wang et al. CLINICAL CANCER RESEARCH
- Preclinical evaluation of 213Bi-/225Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer
- (2020) Sangeeta Ray et al. JOURNAL OF NUCLEAR MEDICINE
- A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals
- (2019) Sai Kiran Sharma et al. NUCLEAR MEDICINE AND BIOLOGY
- Development of Targeted Alpha Particle Therapy for Solid Tumors
- (2019) Narges K. Tafreshi et al. MOLECULES
- The in vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier
- (2019) R. M. de Kruijff et al. Scientific Reports
- Loss of PSMA Expression in Non-neuroendocrine Dedifferentiated Acinar Prostate Cancer
- (2018) Peter Bronsert et al. CLINICAL NUCLEAR MEDICINE
- Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer
- (2018) Jun Hao et al. EUROPEAN UROLOGY
- Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
- (2018) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Salivary gland toxicity of PSMA Radioligand Therapy: relevance and preventive strategies
- (2018) Thomas Langbein et al. JOURNAL OF NUCLEAR MEDICINE
- Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
- (2018) Clemens Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators
- (2018) Ján Kozempel et al. MOLECULES
- Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer
- (2018) Michael R. McDevitt et al. Nature Communications
- Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma
- (2018) Sophie Poty et al. CLINICAL CANCER RESEARCH
- Neuroendocrine differentiation of prostate cancer leads to PSMA suppression
- (2018) Martin K Bakht et al. ENDOCRINE-RELATED CANCER
- The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer
- (2015) Shusuke Akamatsu et al. Cell Reports
- Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with 225Ac for -Particle Radioimmunotherapy of Cancer
- (2014) W. F. Maguire et al. JOURNAL OF NUCLEAR MEDICINE
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis
- (2012) Markus Essler et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody
- (2011) J Schwartz et al. PHYSICS IN MEDICINE AND BIOLOGY
- Targeting Prostate Cancer Cells In Vivo Using a Rapidly Internalizing Novel Human Single-Chain Antibody Fragment
- (2010) J. He et al. JOURNAL OF NUCLEAR MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now